Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$14.72 USD
-0.31 (-2.06%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $14.70 -0.02 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Income Statements
Fiscal Year end for Entrada Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 129 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 129 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 132 | 97 | 51 | 27 | 12 |
Income After Depreciation & Amortization | -3 | -97 | -51 | -27 | -12 |
Non-Operating Income | 15 | 3 | 0 | 0 | 7 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 12 | -95 | -51 | -27 | -5 |
Income Taxes | 19 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -7 | -95 | -51 | -27 | -5 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -7 | -95 | -51 | -27 | -5 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -95 | -50 | -26 | -12 |
Depreciation & Amortization (Cash Flow) | -3 | 2 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -3 | -97 | -51 | -27 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 33.05 | 31.29 | 6.27 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.20 | -3.02 | -8.16 | NA | NA |
Diluted Net EPS (GAAP) | -0.20 | -3.02 | -8.16 | -24.00 | NA |
Fiscal Year end for Entrada Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 94.69 | 59.12 | 41.85 | 43.74 | 18.17 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 94.69 | 59.12 | 41.85 | 43.74 | 18.17 |
SG&A, R&D, and Dept/Amort Expenses | 41.28 | 38.01 | 36.94 | 29.72 | 34.47 |
Income After SG&A, R&D, and Dept/Amort Expenses | 53.41 | 21.11 | 4.91 | 14.02 | -16.30 |
Non-Operating Income | 4.37 | 4.21 | 4.29 | 4.05 | 4.22 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 57.79 | 25.33 | 9.20 | 18.06 | -12.08 |
Income Taxes | 2.76 | 1.83 | 18.74 | -17.40 | 13.85 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 55.03 | 23.50 | -9.54 | 35.46 | -25.93 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 55.03 | 23.50 | -9.54 | 35.46 | -25.93 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 35.51 | 34.79 | 33.37 | 34.78 | 33.16 |
Diluted EPS Before Non-Recurring Items | 1.55 | 0.68 | -0.29 | 1.02 | -0.78 |
Diluted Net EPS (GAAP) | 1.55 | 0.68 | -0.23 | 1.02 | -0.78 |